AX 1505 - Axim Biotech

Drug Profile

AX 1505 - Axim Biotech

Alternative Names: AX-1505

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator Axim Biotech
  • Class Cannabinoids
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Crohn's disease

Most Recent Events

  • 09 Nov 2016 Preclinical trials in Crohn's disease in USA (PO)
  • 09 Nov 2016 Axim Bitoech announces intention to submit NDA in 2020 (Axim Biotech pipeline, November 2016)
  • 09 Nov 2016 Axim Biotech plans a phase IIa trial for Crohn's disease in USA (Axim Biotech pipeline, November 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top